Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study

格列美脲 利拉鲁肽 二甲双胍 医学 2型糖尿病 安慰剂 减肥 内科学 联合疗法 糖尿病 胃肠病学 内分泌学 泌尿科 肥胖 替代医学 病理
作者
Michael A. Nauck,Anders Frid,Kjeld Hermansen,Anne Bloch Thomsen,Maria Düring,Nasir Shah,Tsvetalina Tankova,Ismail Mitha,David R. Matthews
出处
期刊:Diabetes, Obesity and Metabolism [Wiley]
卷期号:15 (3): 204-212 被引量:123
标识
DOI:10.1111/dom.12012
摘要

Aims To investigate efficacy and safety of dual therapy with liraglutide and metformin in comparison to glimepiride and metformin, and metformin monotherapy over 2 years in patients with type 2 diabetes. Methods In the 26-week the Liraglutide Effect and Action in Diabetes (LEAD)-2 core trial, patients (n = 1091) were randomized (2 : 2 : 2 : 1: 2) to liraglutide (0.6, 1.2 or 1.8 mg once-daily), placebo or glimepiride; all with metformin. Patients were enrolled if they were 18–80 years old with HbA1c 7.0–11.0% (previous monotherapy ≥3 months), or 7.0–10.0% (previous combination therapy ≥3 months), and body mass index ≤40 kg/m2. Patients completing the 26-week double-blinded phase could enter an 18-month open-label extension. Results HbA1c decreased significantly with liraglutide (0.4% with 0.6 mg, 0.6% with 1.2 and 1.8 mg) versus 0.3% increase with metformin monotherapy (p < 0.0001). HbA1c decrease with liraglutide was non-inferior versus 0.5% decrease with glimepiride. Liraglutide groups experienced significant weight loss (2.1, 3.0 and 2.9 kg with 0.6, 1.2 and 1.8 mg, respectively) compared to weight gain (0.7 kg) with glimepiride (p < 0.0001). Weight loss with liraglutide 1.2 and 1.8 mg was significantly greater than with metformin monotherapy (1.8 kg; p = 0.0185 and p = 0.0378 for 1.2 and 1.8 mg, respectively). The occurrence of minor hypoglycaemia was <5.0% in all liraglutide groups, significantly less than with glimepiride (24.0%; p < 0.0001). Liraglutide was well tolerated overall: gastrointestinal events were more common than with glimepiride or metformin monotherapy, but occurrence decreased with time. Conclusions Liraglutide provided sustained glycaemic control over 2 years comparable to that provided by glimepiride. Liraglutide was well tolerated, and was associated with weight loss and a low rate of hypoglycaemia.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
威武的沂完成签到,获得积分10
5秒前
7秒前
8秒前
10秒前
笨笨青筠完成签到 ,获得积分10
13秒前
mengmenglv完成签到 ,获得积分0
13秒前
Tonald Yang完成签到 ,获得积分20
16秒前
17秒前
落后的怀梦完成签到 ,获得积分10
18秒前
陈坤完成签到,获得积分10
20秒前
量子星尘发布了新的文献求助10
22秒前
斯文败类应助zgx采纳,获得10
23秒前
默默完成签到 ,获得积分10
23秒前
KY Mr.WANG完成签到,获得积分10
23秒前
37秒前
guoxingliu完成签到,获得积分10
41秒前
49秒前
阳佟水蓉完成签到,获得积分10
50秒前
gdgd完成签到,获得积分10
53秒前
量子星尘发布了新的文献求助10
55秒前
叮叮当当完成签到,获得积分10
57秒前
1分钟前
1分钟前
电致阿光完成签到,获得积分10
1分钟前
ccc完成签到 ,获得积分10
1分钟前
1分钟前
zgx发布了新的文献求助10
1分钟前
i2stay完成签到,获得积分10
1分钟前
馒头完成签到,获得积分10
1分钟前
MS903完成签到,获得积分10
1分钟前
CJW完成签到 ,获得积分10
1分钟前
韧迹完成签到 ,获得积分0
1分钟前
mmd完成签到 ,获得积分10
1分钟前
七一安完成签到 ,获得积分10
1分钟前
浪麻麻完成签到 ,获得积分10
1分钟前
包容的剑完成签到 ,获得积分10
1分钟前
等待的大炮完成签到,获得积分10
1分钟前
注水萝卜完成签到 ,获得积分10
1分钟前
Chem34完成签到,获得积分10
1分钟前
1分钟前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038039
求助须知:如何正确求助?哪些是违规求助? 3575756
关于积分的说明 11373782
捐赠科研通 3305574
什么是DOI,文献DOI怎么找? 1819239
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022